Budesonide (Inhaled)
Brand names: Pulmicort, Symbicort component
This is inhaled budesonide, a corticosteroid used as regular preventer therapy for asthma and as maintenance anti-inflammatory treatment in COPD, taken to reduce airway inflammation and exacerbations.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
The inhaled glucocorticoid binds airway glucocorticoid receptors to suppress local inflammation and reduce bronchial hyper-responsiveness.
Prescribing in practice
- Most important: it is a preventer that must be used regularly and does not relieve an acute attack, so a short-acting reliever must remain available.
- Confirm correct technique for the specific device and consider a spacer with a metered-dose inhaler to improve deposition.
- Use the lowest effective dose to maintain control and review periodically.
Monitoring
Monitor asthma or COPD control, inhaler technique, oral candidiasis, and childhood growth on prolonged use.
Counselling the patient
- Rinse the mouth after inhaling to reduce thrush and hoarseness.
- Continue daily even when symptom-free, as the protective effect is cumulative.
Evidence & guidelines
Inhaled budesonide is well established as preventer therapy in NICE and GINA asthma guidance and within COPD combination regimens.
Reference: GINA 2024; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024